

March 3, 2014



Navidea Biopharmaceuticals to Announce Fourth Quarter and Full-Year 2013 Financial Results on Thursday, March 6, 2014

– Webcast and conference call with investment community at 8:30 a.m. ET –

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the fourth quarter and full-year 2013, on Thursday, March 6, 2014 before the market opens. Company management will host a conference call and slide presentation via webcast, also on March 6, 2014, at 8:30 a.m. ET to discuss results and corporate developments.

Investors and the public are invited to access the live webcast through the link below. Participants who would like to ask questions during the question and answer session following the presentation must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference call begins. The webcast replay is expected to be available on our investor website, <http://ir.navidea.com>, approximately two to four hours after the live event.

Event: Navidea Biopharmaceuticals Q4 2013 and Full-Year Financial Results Conference Call

Date/Time: Thursday, March 6, 2014 at 8:30 a.m. ET

Webcast Link: <http://www.media-server.com/m/p/dh2x4bbc>

Dial-in Number – US: 1 (800) 708-4539

Dial in Number – Int'l: 1 (847) 619-6396

Participant Passcode: 36792037

Replay A webcast replay will be available on the Investor Relations section of our website at <http://ir.navidea.com>

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is developing multiple precision diagnostic products and platforms including NAV4694, NAV5001, Manocept™ and NAV1800 (RIGScan™), to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. [Lymphoseek®](#) (technetium 99m tilmanocept) Injection, Navidea's first commercial product from the Manocept platform, was approved by the FDA in March 2013. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and

commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals

Brent Larson, 614-822-2330

Executive VP & CFO

or

Sharon Correia, 978-655-2686

Associate Director, Corporate Communications

Source: Navidea Biopharmaceuticals, Inc.